2-arachidonoylglycerol (2-AG) is the most abundant Endocannabinoid System lipid mediator in the brain, functioning as a retrograde Neurotransmitters that inhibits synaptic transmission and modulates immune responses. Synthesized on-demand from membrane phospholipids, it binds primarily to CB1 receptor (CNS) and CB2 receptors (peripheral immune), regulating pain perception, inflammation, neuroplasticity, emotional responses, and metabolic homeostasis. Its concentration in brain tissue is approximately 1000-fold higher than anandamide, making it the dominant endocannabinoid tone-setter.
Imagine your synapse as a factory production line where workers (presynaptic neurons) are frantically assembling products (neurotransmitters) and shipping them across the conveyor belt (synaptic cleft). When the receiving dock (postsynaptic neuron) gets overwhelmed, it doesn't just passively accept more deliveries — it sends a messenger running backward across the factory floor, yelling "SLOW DOWN!" That messenger is 2-AG.
The postsynaptic cell literally manufactures 2-AG on the spot from its own cell membrane (like tearing a page from your notebook to write the urgent message), and this lipid molecule travels retrograde — against the normal direction of traffic — to tap the shipping department on the shoulder and activate the CB1 "brake pedal" receptor. The workers immediately reduce production. The entire message lifecycle is brief: 2-AG is rapidly degraded by MAGL enzymes within seconds, like the note self-destructing once read.
Meanwhile, 2-AG also acts as a diplomat to the immune system. When macrophages and microglia arrive at an injury site ready to launch inflammatory artillery, 2-AG binds their CB2 receptors and whispers, "Easy now — resolution, not destruction." It's the body's internal cannabis, produced exactly where and when needed, preventing both neuronal hyperexcitability and immune overreaction. During stress, your periaqueductal gray floods with 2-AG, creating stress-induced analgesia — the reason soldiers don't feel wounds mid-battle.
Postsynaptic neuronal depolarization + Ca²⁺ influx → activation of phospholipase C (PLC) → cleavage of membrane phosphatidylinositol 4,5-bisphosphate (PIP2) → diacylglycerol (DAG) production → diacylglycerol lipase-α (DAGLα) cleaves DAG → 2-AG release
Alternative pathway: Phospholipase A1 → lysophosphatidylinositol → DAGLα → 2-AG
2-AG diffuses retrograde across synaptic cleft → binds presynaptic CB1 receptor (Gi/o-coupled GPCR) → inhibits adenylyl cyclase → reduces cAMP → decreases PKA activity → closes voltage-gated Calcium channels (N-type, P/Q-type) → reduced neurotransmitter release (glutamate, GABA, dopamine, serotonin)
Simultaneous activation of inward-rectifying K⁺ channels → hyperpolarization → further suppression of neurotransmitter vesicle fusion
2-AG binds CB2 receptors on macrophages, microglia, leukocytes → Gi/o signaling → inhibits NF-κB translocation → reduces IL-1β, IL-6, TNF-α production → suppresses NLRP3 inflammasome activation → promotes M2 macrophage polarization
Also activates β-arrestin pathway → ERK1/2 phosphorylation → anti-apoptotic signals in immune cells
Monoacylglycerol lipase (MAGL, ~85% of degradation) cleaves 2-AG → arachidonic acid + glycerol
Alternative: ABHD6 (~4%), ABHD12 (minor)
Half-life in synaptic space: ~1-10 seconds
2-AG → COX-2 (when upregulated) → prostaglandin glycerol esters (PG-Gs) with distinct inflammatory roles
2-AG → 15-LOX → glycerol esters of hydroxyeicosatetraenoic acids
Deficient 2-AG signaling is a hallmark of chronic pain states. In fibromyalgia, migraine, and irritable bowel syndrome, patients show reduced 2-AG levels and impaired CB1 receptor density, creating endocannabinoid deficiency syndrome. This explains why these conditions respond to cannabinoid-based interventions and why stress management (which elevates 2-AG) provides relief.
The PAG-raphe-spinal descending pain modulation system relies on 2-AG as its primary brake pedal. During placebo analgesia, CB1 antagonists completely block the effect — proving placebo analgesia is literally endocannabinoid-mediated. Clinical implication: context manipulation, therapeutic ritual, and conditioning can elevate endogenous 2-AG more safely than exogenous cannabinoids.
2-AG levels are critically low in PTSD patients, particularly in the prefrontal cortex and amygdala. Fear extinction training (the basis of exposure therapy) requires 2-AG-mediated CB1 activation to consolidate new safety memories. MAGL inhibitors that slow 2-AG degradation show promise for enhancing psychotherapy outcomes without psychoactive effects.
Unlike classical anti-inflammatories that merely suppress, 2-AG actively promotes inflammatory resolution by shifting macrophage phenotype from M1 to M2, enhancing efferocytosis, and terminating NLRP3 inflammasome activity. This positions it within the broader specialized pro-resolving mediators family, though via different receptors.
Excessive 2-AG in adipose tissue and liver contributes to obesity, insulin resistance, and NAFLD via peripheral CB1 activation. This creates a paradox: CNS 2-AG is analgesic and anxiolytic; peripheral 2-AG is obesogenic. Peripheral-specific CB1 blockers are in development to exploit this tissue-specific difference.
The 5 plus 2 metamodel approach: chronic low-grade inflammation and psychological stress both dysregulate 2-AG synthesis. Intermittent Living practices (cold exposure, fasting, exercise) upregulate DAGLα expression. Omega-3 supplementation provides alternative substrates, shifting away from arachidonic acid-derived 2-AG toward less inflammatory variants. Mindfulness and Cognitive Immune System training enhance context-dependent 2-AG release (the placebo pathway).